Connect public, paid and private patent data with Google Patents Public Datasets

Drug delivery device and method for bi-directional drug delivery

Download PDF

Info

Publication number
US20040249449A1
US20040249449A1 US10456432 US45643203A US2004249449A1 US 20040249449 A1 US20040249449 A1 US 20040249449A1 US 10456432 US10456432 US 10456432 US 45643203 A US45643203 A US 45643203A US 2004249449 A1 US2004249449 A1 US 2004249449A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
therapeutic
agents
device
agent
surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10456432
Other versions
US7169179B2 (en )
Inventor
John Shanley
Theodore Parker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovational Holdings LLC
Original Assignee
Conor Medsystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/91533Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
    • A61F2002/91541Adjacent bands are arranged out of phase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/9155Adjacent bands being connected to each other
    • A61F2002/91558Adjacent bands being connected to each other connected peak to peak
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Abstract

A drug delivery device is provided with openings for directional delivery of a plurality of therapeutic agents to blood vessels or other lumens or organs. In particular, the invention relates to the delivery of different therapeutic agents, different quantities of therapeutic agents, or different release profiles of the same or different therapeutic agents in different directions from the drug delivery device. The invention is useful, for example, for delivering antirestenotic, antithrombotic, antiplatelet, antiproliferative, antineoplastic, immunosuppressive, angiogenic, anti-inflammatory, or antiangiogenic agents and/or vasodilators to a blood vessel. In one embodiment, antiproliferative, antineoplastic, angiogenic, antiangiogenic, anti-inflammatory, and/or antirestenotic agents are delivered to the wall of a blood vessel and antithrombotic agents, antiplatelet agents, and/or vasodilators are delivered to the lumen of a blood vessel.

Description

    BACKGROUND OF THE INVENTION FIELD OF THE INVENTION
  • [0001]
    The invention relates to the use of a drug delivery device with openings to deliver a plurality of beneficial agents to bodily lumens. In particular, the invention relates to the delivery of different beneficial agents, different quantities of beneficial agents, or different release profiles of the same or different beneficial agents in different directions from the drug delivery device.
  • REFERENCES
  • [0002]
    Allison, A. C. (2000) Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology. 47:63-83;
  • [0003]
    Dogne, J. M. et al. (2002) Recent advances in antiplatelet agents. Curr. Med. Chem. 9:577-89;
  • [0004]
    Kirsten, R. et al. (1998) Clinical pharmacokinetics of vasodilators. Part I. Clin. Pharmacokinet. 34:457-82;
  • [0005]
    Kirsten, R. et al. (1998) Clinical pharmacokinetics of vasodilators. Part II. Clin. Pharmacokinet. 35:9-36;
  • [0006]
    Kitakaze, M. et al. (2002) Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: role of bradykinin. J. Am. Coll. Cardiol. 40:162-6;
  • [0007]
    Oikawa, Y. et al. (2001) Attenuation of angiotensin II-mediated coronary vasoconstriction and vasodilatory action of angiotensin-converting enzyme inhibitor in pacing-induced heart failure in dogs. J. Am. Coll. Cardiol. 38:1188-94;
  • [0008]
    Physicians' Desk Reference (2001) Medical Economics Co., Inc., Montvale, N.J.;
  • [0009]
    Sun, Y. P. et al. (2001) Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J. Cardiovasc. Pharmacol. Ther. 6:175-81;
  • [0010]
    Tanoue, A. et al. (2001) The alpha(1D)-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J. Clin. Invest. 109:765-75;
  • [0011]
    U.S. Pat. No. 4,446,325;
  • [0012]
    U.S. Pat. No. 4,733,665;
  • [0013]
    U.S. Pat. No. 4,733,665;
  • [0014]
    U.S. Pat. No. 4,733,665;
  • [0015]
    U.S. Pat. No. 4,739,762;
  • [0016]
    U.S. Pat. No. 4,739,762;
  • [0017]
    U.S. Pat. No. 4,776,337;
  • [0018]
    U.S. Pat. No. 4,776,337;
  • [0019]
    U.S. Pat. No. 4,776,337;
  • [0020]
    U.S. Pat. No. 4,969,458;
  • [0021]
    U.S. Pat. No. 5,116,861;
  • [0022]
    U.S. Pat. No. 5,284,834;
  • [0023]
    U.S. Pat. No. 5,716,981;
  • [0024]
    U.S. Pat. No. 5,972,965;
  • [0025]
    U.S. Pat. No. 6,241,762;
  • [0026]
    U.S. Pat. No. 6,440,948;
  • [0027]
    U.S. Pat. No. 6,476,037;
  • [0028]
    U.S. Pat. No. 6,489,298;
  • [0029]
    Van Aken, H. et al. (2001) Anticoagulation: the present and future. Clin. Appl. Thromb. Hemost. 7:195-204;
  • SUMMARY OF THE RELATED ART
  • [0030]
    Permanent and biodegradable devices have been developed for implantation within a body passageway to maintain patency of the passageway. These devices have typically been introduced percutaneously, and transported transluminally until positioned at a desired location. These devices are then expanded either mechanically, such as by the expansion of a mandrel or balloon positioned inside the device, or expand themselves by releasing stored energy upon actuation within the body. Once expanded within the lumen, these devices, called stents, become encapsulated within the body tissue and remain a permanent implant.
  • [0031]
    Known stent designs include monofilament wire coil stents (U.S. Pat. No. 4,969,458); welded metal cages (U.S. Pat. Nos. 4,733,665 and 4,776,337); and thin-walled metal cylinders with axial slots formed around the circumference (U.S. Pat. Nos. 4,733,665; 4,739,762; and 4,776,337). Known construction materials for use in stents include polymers, organic fabrics, and biocompatible metals, such as, stainless steel, gold, silver, tantalum, titanium, and shape memory alloys such as Nitinol.
  • [0032]
    U.S. Pat. Nos. 4,733,665; 4,739,762; and 4,776,337 disclose expandable and deformable interluminal vascular grafts in the form of thin-walled tubular members with axial slots allowing the members to be expanded radially outwardly into contact with a body passageway. After insertion, the tubular members are mechanically expanded beyond their elastic limit and thus permanently fixed within the body.
  • [0033]
    Coated stents, designed to release various beneficial agents, have shown promising results in reducing restenosis, a condition commonly associated with stent implantation. For example, U.S. Pat. No. 5,716,981 discloses a stent that is surface-coated with an agent comprising a polymer carrier and Paclitaxel, a well-known tubulin assembly stabilizer that is commonly used in the treatment of cancerous tumors.
  • [0034]
    In addition, several U.S. patents describe the use of stents to deliver angiogenic agents (U.S. Pat. Nos. 6,479,654; 6,475,779; and 6,363,938), antithrombotic (antiplatelet) agents (U.S. Pat. Nos. 6,071,514 and 5,383,928), anticoagulants (U.S. Pat. No. 6,273,908), or combinations thereof (U.S. Pat. No. 6,231,600).
  • [0035]
    However, a major technological obstacle facing the use of stents for the delivery of angiogenic agents is the thickness of the stent coating. Stent coatings are necessarily very thin, typically 5 to 8 microns. Since the surface area of the stent is comparatively large, the entire volume of the beneficial agent has a very short diffusion path to discharge into the surrounding tissue. This issue is especially problematic for therapies that require the prolonged delivery of a beneficial agent. While increasing the thickness of the surface coating improves drug release kinetics, it also results in an undesirable increase in overall stent thickness.
  • [0036]
    Moreover, existing methods of drug delivery using coated stents are unable to selectively deliver beneficial agents to only one side of the stent surface and are unable to deliver different beneficial agents to different surfaces of the implanted stent, for example, the exterior surface adjacent to the wall of the blood vessel and the interior surface exposed to the lumen of the blood vessel.
  • [0037]
    The instant invention satisfies a need in the art by providing a medical device that can provide different beneficial agents, different quantities of beneficial agents, or different release profiles of the same or different beneficial agents in different directions with respect to the surfaces of the medical device.
  • SUMMARY OF THE INVENTION
  • [0038]
    In accordance with one embodiment of the invention, a drug delivery device includes first and second therapeutic agents arranged for delivery in different directions.
  • [0039]
    In one embodiment, a method of delivering therapeutic agents comprises the steps of providing a medical device comprising an exterior surface and an interior surface, and first and second therapeutic agents in openings in the medical device, implanting the medical device with the therapeutic agents in a patient, releasing the first therapeutic agent predominantly in a direction of said exterior surface of the medical device over a time period sufficient to produce a therapeutic effect, and releasing the second therapeutic agent predominantly in a direction of said interior surface of the medical device over a time period sufficient to produce a therapeutic effect.
  • [0040]
    In another embodiment, a method of delivering two or more therapeutic agents, to a blood vessel includes providing a substantially cylindrical medical device having an exterior surface, an interior surface, and openings traversing said exterior surface and said interior surface, said openings having a barrier layer arranged at a radially intermediate surface with respect to said exterior surface and said interior surface, wherein at least one first therapeutic agent is disposed in a therapeutic layer disposed at a radially exterior surface with respect to said barrier layer and wherein at least one second therapeutic agent is disposed in a therapeutic layer disposed at a radially interior surface with respect to said barrier layer, delivering the medical device with the therapeutic agents to a lumen of a blood vessel, and releasing the therapeutic agents over a time period sufficient to produce a therapeutic effect, wherein the first therapeutic agent is released substantially toward said exterior surface of the medical device and wherein the second therapeutic agent is released substantially toward said interior surface of the medical device.
  • [0041]
    In a further embodiment, a method of delivering therapeutic agents to a blood vessel comprises providing a medical device comprising a first surface, a second surface, and openings traversing said first surface and said second surface, said openings containing therapeutic agents, delivering the medical device with the therapeutic agents to a lumen of a blood vessel, and releasing a first of the therapeutic agents to a wall of the blood vessel over a time period sufficient to produce a therapeutic effect, and releasing a second of the therapeutic agents to the lumen of the blood vessel over a time period sufficient to produce a therapeutic effect.
  • [0042]
    In another embodment, a drug delivery device comprises a medical device having an exterior surface and an interior surface, a plurality of openings in the device body, and a first therapeutic agent and a second therapeutic agent disposed in the openings and arranged to deliver the first therapeutic agent primarily to the exterior surface and to deliver the second therapeutic agent primarily to the interior surface.
  • [0043]
    In a further embodiment, a drug delivery device comprises an exterior surface, an interior surface, a plurality of openings traversing said exterior surface and said interior surface, said openings having a barrier layer arranged at a radially intermediate position with respect to said exterior surface and said interior surface, at least one first therapeutic agent in a therapeutic layer disposed at a radially exterior position with respect to said barrier layer, and at least one second therapeutic agent in a therapeutic layer disposed at a radially interior position with respect to said barrier layer.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0044]
    The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
  • [0045]
    [0045]FIG. 1 is a perspective view of a portion of a medical device with beneficial agent implanted in the lumen of a blood vessel.
  • [0046]
    [0046]FIG. 2 is an enlarged cross-section of a portion of a medical device with openings illustrating two beneficial agents provided in one opening for bi-directional delivery.
  • [0047]
    [0047]FIG. 3 is an enlarged cross-section of a portion of a medical device with openings illustrating a plurality of beneficial agents provided for bi-directional delivery from multiple openings.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • [0048]
    Definitions
  • [0049]
    As used herein, the following terms have the following meanings:
  • [0050]
    Angiogenesis: The process by which a capillary network gives rise to additional branches, extensions, and connections.
  • [0051]
    Angiogenic agents: Agents that act to modulate angiogenesis.
  • [0052]
    Angiogenic factors: Angiogenic polypeptides.
  • [0053]
    Anti-inflammatory agent: Agents that act to reduce in intensity or duration the physiologic process of inflammation.
  • [0054]
    Antiplatelet agents: Agents that act to inhibit or decrease platelet aggregation and/or clot formation or otherwise modulate the aggregation and/or clotting activity of platelets. Used herein as synonymous with antithrombotic agents.
  • [0055]
    Antiproliferative agents: Agents that act to modulate cell proliferation, including cell proliferation resulting from cell transformation, for example, in the cases of cancer, malignancy, neoplasms, and virus-induced cell transformations.
  • [0056]
    Antirestenotic agents: Agents that act to modulate restenosis.
  • [0057]
    Antithrombotic agents: Agents that act to modulate thrombin activity. Used herein as synonymous with antiplatelet agents.
  • [0058]
    Arteriosclerosis: Hardening of the arteries produced by degenerative or hyperplasic changes to the intima of arteries or a progressive increase in muscle and elastic tissue in arterial walls.
  • [0059]
    Atherosclerosis: The most common form of arteriosclerosis characterized by deposits of lipid material in the intima of medium and large diameter arteries, resulting in partial or total occlusion of an affected vessel.
  • [0060]
    Beneficial agent: As used herein, the term “beneficial agent” is intended to have its broadest possible interpretation and is used to include any therapeutic agent or drug, as well as inactive agents such as barrier layers, carrier layers, therapeutic layers, or protective layers.
  • [0061]
    Beneficial layers: Biodegradable layers comprising beneficial agents.
  • [0062]
    Biodegradable: See Bioresorbable, below.
  • [0063]
    Bioresorbable: The characteristic of being bioresorbable and/or able to be broken down by either chemical or physical processes, upon interaction with a physiological environment. For example, a biodegradable or bioerodible matrix is broken into components that are metabolizable or excretable, over a period of time from minutes to years, preferably less than one year, while maintaining any requisite structural integrity in that same time period.
  • [0064]
    Erosion: The process by which components of a medium or matrix are bioresorbed and/or degraded and/or broken down by chemical or physical processes. For example in reference to biodegradable polymer matrices, erosion can occur by cleavage or hydrolysis of the polymer chains, thereby increasing the solubility of the matrix and suspended beneficial agents.
  • [0065]
    Erosion rate: A measure of the amount of time it takes for the erosion process to occur, usually reported in unit-area per unit-time.
  • [0066]
    Hypoxia: Condition characterized by an abnormally low oxygen concentration in affected tissues.
  • [0067]
    Implantation site: A site into which a medical device or stent is physically implanted.
  • [0068]
    Ischemia: Local anemia resulting from obstructed blood flow to an affected tissue.
  • [0069]
    Matrix or bioresorbable matrix: The terms “matrix” or “bioresorbable matrix” are used interchangeably to refer to a medium or material that, upon implantation in a subject, does not elicit a detrimental response sufficient to result in the rejection of the matrix. The matrix typically does not provide any therapeutic responses itself, though the matrix may contain or surround a beneficial agent, as defined herein. A matrix is also a medium that may simply provide support, structural integrity or structural barriers. The matrix may be polymeric, non-polymeric, hydrophobic, hydrophilic, lipophilic, amphiphilic, and the like.
  • [0070]
    Openings: The term “openings” includes both through openings and recesses.
  • [0071]
    Pharmaceutically acceptable: The characteristic of being non-toxic to a host or patient and suitable for maintaining the stability of a beneficial agent and allowing the delivery of the beneficial agent to target cells or tissue.
  • [0072]
    Primarily: With respect to directional delivery, primarily refers to an amount greater than about 50% of the total amount of beneficial agent provided to a blood vessel.
  • [0073]
    Radially inner or radially interior surface: With respect to medical device struts, a radially inner or interior surface refers to a surface that has a substantially equivalent radius to that of the interior strut surface.
  • [0074]
    Radially intermediate surface: With respect to medical device struts, a radially intermediate surface refers to a surface that has a substantially equivalent radius intermediate between that of the interior and exterior strut surfaces.
  • [0075]
    Restenosis: The recurrence of stenosis after a surgical procedure, including the infiltration of smooth muscle cells into the bore of a medical device implanted to correct a previous chronic occlusion.
  • [0076]
    Sequential delivery: Delivery of beneficial agents in a specified sequence, for example where about 75% of a first agent is delivered before about 50% of a second agent is delivered.
  • [0077]
    Stenosis: A restriction or occlusion of any vessel or orifice.
  • [0078]
    Therapeutic agent: Refers to any therapeutically active substance that is delivered to a bodily conduit of a living being to produce a desired, usually beneficial, effect. The present invention is particularly well suited for the delivery of antineoplastic, angiogenic factors, immuno-suppressants, and antiproliferatives (anti-restenosis agents) such as paclitaxel and Rapamycin for example, and antithrombins such as heparin, for example.
  • [0079]
    Thrombosis: The formation of a thrombus (clot) within a blood vessel, often leading to partial or total occlusion of the blood vessel, leading to a condition of hypoxia in tissues supplied by the occluded blood vessel.
  • [0080]
    Vasodilators (or vasodilative agents): Polypeptides, polynucleotides encoding polypeptides, small molecules, or combinations thereof, that cause blood vessel dilation, i.e., an increase in the lumen of a blood vessel.
  • [0081]
    The present invention relates to the use of medical devices, and more particularly to the use of implantable medical devices having a plurality of openings in non-deforming strut and/or link elements, to deliver therapeutic agents to an implantation site over an extended period of time. In particular, the invention relates to medical devices for directional delivery of therapeutic agents and the use of medical devices to deliver different therapeutic agents, different quantities of therapeutic agents, or different release profiles of the same or different therapeutic agents in different directions with respect to the surfaces of the medical device.
  • [0082]
    The implantable bi-directional agent delivery device is useful, for example, for delivering antirestenotic, antithrombotic, antiplatelet, antiproliferative, antineoplastic, immunosuppressive, angiogenic, antiangiogenic agents, anti-inflammatories, and/or vasodilators to a blood vessel. In one embodiment of the invention, antiproliferative, antineoplastic, angiogenic, antiangiogenic, anti-inflammatory, and/or antirestenotic agents are delivered to the wall of a blood vessel and antithrombotic, antiplatelet agents, and/or vasodilators are delivered to the lumen of a blood vessel. The bi-directional delivery device can be used in many therapies particularly those where a first agent has been known to be delivered from a stent while a second agent is delivered systemically. The bi-directional delivery allows the systemically delivered agent to be delivered by the same device as the first agent.
  • [0083]
    [0083]FIG. 1 illustrates a portion of one example of a medical device 10 of the present invention shown disposed longitudinally in a blood vessel. FIGS. 2 and 3 show two examples of the medical device 10 of FIG. 1 in further detail. The device 10 is formed of struts and links (collectively referred to herein as struts 12) which are interconnected by ductile hinges 40. The device 10 includes openings 14 containing one or more agents. In the example of FIG. 1, a plurality of struts 12 include substantially rectangular openings 14, while other struts include substantially circular openings 42. Bridging elements 44 connect adjacent stent segments and include an arrangement of substantially D-shaped openings 46 for containing a beneficial agent. The struts 14 and portions of the bridging elements 44 having openings 14, 42, 46 are nondeforming.
  • [0084]
    In the embodiment of FIG. 1, the ductile hinges 40 allow expansion and/or compression of the medical device 10 while allowing the struts 12, and thus the openings 14 to remain undeformed during expansion or compression. The portions of the bridging elements 44 containing the openings 46 are also non-deforming. The non-deforming beneficial agent containing openings 14, 42, 46 prevent damage to or altering of the beneficial agent within the openings. The embodiment of FIG. 1 is shown as one example, however, other device structures may also be used.
  • [0085]
    [0085]FIG. 1 is a side view of a portion of the medical device 10 implanted in a lumen of a blood vessel 100. A wall of the blood vessel 100 includes three distinct tissue layers, an intima, a media, and an adventitia. The medical device 10 incorporates some of the features of the medical devices described in U.S. Pat. No. 6,241,762, herein incorporated by reference in its entirety. U.S. Pat. No. 6,241,762 describes a medical device design that remedies performance deficiencies of previous medical devices by the use of ductile hinges and non-deforming struts.
  • [0086]
    The openings 14, 42, 46 in the example of FIG. 1 extend from an exterior surface of the device adjacent the vessel wall to an interior surface or lumenal side of the device. The presence of the openings 14, 42, 46 in the medical device 10 containing beneficial agent provide a number of important advantages. For example, the openings 14, 42, 46 allow the use of a substantially larger volume of beneficial agent than can be used in the case of a coating, increasing the total amount of beneficial agent available for delivery. The ability to dispose beneficial agent in the medical device openings 14 also facilitates the gradual release of beneficial agent over an extended delivery period, compared to the use of a simple coating.
  • [0087]
    In addition, the use of openings 14, 42, 46 that contain a plurality of agents and optional barrier layers, allows the primary release of beneficial agents in one or both directions (inward and outward) relative to the implanted medical device 10 (FIG. 1). In this manner, beneficial agents may be delivered primarily to the exterior surface of the medical device 10 adjacent to the intima of the blood vessel 100, primarily to the interior surface of the medical device 10 exposed to the lumen of the blood vessel 100, or both. A barrier layer in the medical device 10 openings 14, 42, 46 is useful in minimizing diffusion of agents in the direction of the barrier layer allowing directional delivery of the agents.
  • [0088]
    [0088]FIG. 2 is a perspective view of one embodiment of a medical device 10 showing an opening 14 in the struts 12 of the device for bi-directional therapeutic agent delivery. FIG. 3 is an expanded side view of a portion of another embodiment of the medical device 10 of FIG. 1, further showing the arrangement of openings 14 in the struts 12 of the device for bi-directional agent delivery from different openings.
  • [0089]
    An enlarged cross-section view of a portion of a medical device having one or more openings 14, and one or more beneficial agents, is shown in FIG. 2. In general, the openings 14 in the struts 12 may be provided with a barrier layer 18, a first therapeutic agent 16, and a second therapeutic agent 20. In one embodiment of the invention, the total depth of an opening 14 is about 100 to about 140 microns (μM), typically about 125 microns, and the agents are delivered to the opening by depositing layers which may mix together significantly after being deposited in the opening. A typical layer thickness is about 2 to about 50 microns, preferably about 12 microns thick. There would be at least two and preferably about ten to twelve layers deposited in an opening 14, with a total beneficial agent thickness about 25 to about 28 times greater than a typical surface coating. According to one preferred embodiment of the invention, the openings 14 each have a cross-sectional area of at least about 5×10−6 square inches, and preferably at least about 7×10−6 square inches.
  • [0090]
    Since each layer of beneficial agent may be created independently, individual chemical agents and pharmacokinetic properties can be imparted to each layer. Numerous useful arrangements of layers can be formed, some of which will be described below. Each of the layers may include one or more therapeutic agents in the same or different proportions from layer to layer. The layers may be solid, porous, or filled with other drugs or excipients.
  • [0091]
    [0091]FIG. 3 shows a medical device 10 with a simple arrangement of layers in openings 14 with a barrier layer 18 disposed at the exterior surface 24 or interior surface 26 of the strut 12 and the first therapeutic agent 16 and second therapeutic agent 20 arranged adjacent the barrier layer for directional agent delivery. This arrangement is useful, for example, for delivering different therapeutic agents 16, 20 to the vessel wall and to the lumen of the blood vessel 100.
  • [0092]
    The therapeutic agents 16, 20 may be arranged as one or more plugs or layers. The layers may include essentially identical layers of at least one therapeutic agent, layers comprising different concentrations of at least one therapeutic agent, layers comprising different therapeutic agents, or any combination thereof, suspended in biodegradable matrices with the same or different erosion or resorbsion properties. The erosion of the biodegradable matrix results in the release of therapeutic agent at a release rate over time corresponding to the erosion rate of the matrix, providing for a controlled distribution of one or more therapeutic agents. Use of bioresorbable carriers in combination with openings is especially useful, for example, to assure essentially 100% discharge of the therapeutic agent within a predetermined period of time.
  • [0093]
    The concentration of the same therapeutic agents in the layers could be varied from layer to layer, facilitating release profiles of a predetermined shape. Progressively, increasing concentrations of therapeutic agent at layers of greater depth results in the release of the therapeutic agent at an approximately linear rate over time or a zero order delivery profile.
  • [0094]
    Alternatively, different layers may comprise different therapeutic agents, providing the ability to release different therapeutic agents at different times following implantation of the medical device 10. In one embodiment of the invention, the different layers are eroded sequentially such that the majority of the therapeutic agent 16 in a first layer at an outer surface of the device 10 is delivered before the majority of therapeutic agent of the second or underlying layer, and so forth.
  • [0095]
    In FIG. 3, when the barrier layer 18 is disposed at or near the exterior surface 24 of the medical device 10, the release of the adjacent therapeutic agent 20 is directed primarily toward the lumen of the blood vessel. In this embodiment, barrier layers 18 are disposed at or near the external surface 24 in a first subset of openings 14 and disposed at or near an internal surface 26 in a second subset of openings 14 of the medical device 10. Therapeutic agents 16 to be delivered to the wall of a blood vessel 100 upon implantation of the medical device 10 are provided in the openings having the barriers layers 18 disposed at or near the internal surface 26. Therapeutic agents 20 to be delivered to the lumen of the blood vessel upon implantation of the medical device 10 are provided in the openings having the barriers layers 18 disposed at the external surface 24. In this manner, therapeutic agents 16, 20 are delivered primarily in different directions using different subsets of openings 14, where a subset can be any number of openings less than the total number of openings. Agents are delivered primarily in a selected direction when at least 80% of the agent is delivered in the direction or preferably when at least 90% of the agent is delivered in the selected direction.
  • [0096]
    [0096]FIG. 2 illustrates another embodiment of the invention in which the barrier layer 18 is disposed at a radially intermediate position with respect to the exterior surface 24 and interior surface 26 of the medical device. The barrier layer 18 may be disposed essentially equidistant between the exterior 24 and interior 26 surfaces of the medical device 10 or may be disposed closer to either the exterior 24 or interior surface 26. Barrier layers 18 may be disposed at essentially the same radially intermediate positions in all the openings 14 of a medical device 10 or at different radially intermediate locations in different openings of the medical device 10. The presence of the barrier layer 18 creates essentially two independent reservoirs in each opening 14 for providing therapeutic agents 16, 20.
  • [0097]
    As described above, the first and second therapeutic agents 16, 20 and the barrier layer 18 may each be formed by deposition of one or more layers which may mix within the openings after deposition. The layers of therapeutic agent can include essentially identical layers of at least one therapeutic agent, layers comprising different concentrations of at least one therapeutic agent, layers comprising different therapeutic agents, or any combination thereof, suspended in biodegradable matrices with the same or different erosion properties.
  • [0098]
    Barrier layers 18 as shown in FIGS. 2 and 3, can be used to control therapeutic agent release kinetics in several ways. First, a barrier layer 18 with a substantially non-biodegradable barrier material could be used to essentially prevent the diffusion of therapeutic agents 16, 20 in one direction, thereby insuring the delivery of therapeutic agents to essentially one surface of the medical device 10. Barrier layers 18 with predetermined erosion times longer than the erosion times of the biodegradable matrix used in the therapeutic agent layers 16, 20 are also useful for directing therapeutic agents to the exterior or interior surface of the implanted medical device 10 but will eventually erode providing a termination of a treatment at a predetermined time.
  • [0099]
    The erosion rates of individual layers may be further controlled by creating contours on the surfaces of selected layers. For example, ribs on the surface of a layer increase the overall surface area and increase the rate on initial release. Elevated or protruding portions of one layer, e.g., that extend into depressed areas in another layer, cause leading or trailing characteristics of the release profiles of the therapeutic agents in the protruding or depressed layers.
  • [0100]
    In another embodiment of the invention, barrier layers 18 may be disposed in only a subset of the openings 14 in the medical device 10. The subset may comprise any number less than the total number of openings in the medical device. Openings 14 without barrier layers 18 may still be provided with therapeutic agents 16, for example, therapeutic agents intended to be delivered to both the exterior surface 24 and interior surface 26 of the medical device 10.
  • [0101]
    In another alternative, some openings may be provided with therapeutic agent 16 while others are left empty. The empty openings could provide an immediate nidus for the ingrowth of cells and extracellular components to affix the medical device 10 to the blood vessel 100, while the “filled” openings dispense therapeutic agents 16, 20.
  • [0102]
    The first and second therapeutic agents 16, 20 may be provided without a separation barrier layer when the two agents are delivered in opposite directions and are completely delivered at approximately the same time. Alternatively, where some delivery of the first and second therapeutic agents 16, 20 to the side of the medical device 10 other than the primary delivery target is acceptable or desired, the barrier layer 18 may be omitted.
  • [0103]
    A single medical device may comprise any combination of traversing openings, wherein the traversing openings may be provided with barrier layers at different positions or left empty, as described above. For example, a single medical device could comprise openings with barrier layers disposed at the interior surface of the medical device, openings with barrier layers disposed at the exterior surface of the medical device, openings with barrier layers disposed at an intermediate surface of the medical device, and empty openings.
  • [0104]
    In one embodiment of the invention, layers comprising therapeutic agents can be provided in the openings open to the exterior of the medical device, the openings open to the interior of the medical device, in openings without barrier layers, in a subset of openings, or any combinations thereof, thereby providing for the release of therapeutic agents in one or both directions as selected by the practitioner. Each layer may comprise one or more therapeutic agents and each opening may comprise one or more therapeutic layers. The release rates of therapeutic agents could be controlled independently depending on the particular bioresorbable matrix selected to deliver each therapeutic agent or each combination of therapeutic agents. Release rates and release profiles can also be controlled by adding separating layers, modification of layer thickness, selection of matrix material, and many other factors.
  • [0105]
    In one embodiment of the invention, one or more antiproliferative, antineoplastic, antiangiogenic, angiogenic, anti-inflammatory, and/or antirestenotic agents are provided in the openings open to the exterior 24 of the medical device 10 for delivery to the wall of the blood vessel 100. Also in one embodiment of the invention, one or more antithrombotic agents, antiplatelet agents, anti-inflammatory and/or vasodilators are provided in the openings open to the inside surface 26 of the medical device 10 for delivery to the lumen 116 of a blood vessel.
  • [0106]
    The therapeutic agents for use with the present invention also include classical low molecular weight therapeutic agents (commonly referred to as drugs) including but not limited to immunosuppressants, antilipid agents, anti-inflammatory agents, vitamins, antimitotics, metalloproteinase inhibitors, NO donors, estradiols, anti-sclerosing agents, and vasoactive agents, alone or in combinations with any therapeutic agent mentioned herein. Therapeutic agents also include peptides, polypeptides, polynucleotides encoding polypeptides, lipids, protein-drugs, enzymes, oligonucleotides and their derivatives, ribozymes, other genetic material, prions, viruses, bacteria, and eukaryotic cells such as endothelial cells, monocyte/macrophages or vascular smooth muscle cells to name but a few examples. The therapeutic agent may also be a pro-drug, which metabolizes into the desired drug when administered to a host. In addition, therapeutic agents may be pre-formulated as microcapsules, microspheres, microbubbles, liposomes, niosomes, emulsions, dispersions or the like before they are incorporated into the therapeutic layer. Therapeutic agents may also be radioactive isotopes or agents activated by some other form of energy such as light or ultrasonic energy, or by other circulating molecules that can be systemically administered. Therapeutic agents may perform multiple functions including modulating angiogenesis, restenosis, cell proliferation, thrombosis, platelet aggregation, clotting and vasodilation. Anti-inflammatories include non-steroidal anti-inflammatories (NSAID), such as aryl acetic acid derivatives, e.g., Diclofenac; aryl propionic acid derivatives, e.g., Naproxen; and salicylic acid derivatives, e.g., aspirin, Diflunisal. Anti-inflammatories also include glucocoriticoids (steroids) such as dexamethasone, prednisolone, and triamcinolone. Anti-inflammatories may be used in combination with antiproliferatives to mitigate the reaction of the tissue to the antiproliferative.
  • [0107]
    The therapeutic agents delivered by the medical device of the present invention may be arranged for delivery uniformly from the entire interior and exterior surfaces of the device. Alternatively, the delivery locations of the therapeutic agents may be arranged such that two or more agents are delivered from different areas of the device. For example, a first therapeutic agent may be delivered to the wall of the blood vessel at the ends of a cylindrical medical device, a second therapeutic agent may be delivered uniformly to the lumen of the blood vessel, and a third therapeutic agent may be delivered to the vessel wall at an interior portion of the cylindrical device between the ends.
  • [0108]
    Although the present invention has been described as a generally cylindrical expandable medical device for use as a stent in a blood vessel, the device can also take on different configurations for implantations in other lumens or organs within the body where it is desirable to have directional delivery of two or more therapeutic agents.
  • [0109]
    In the illustrated embodiments, the therapeutic agents are delivered directly to the wall or lumen of the blood vessel. The therapeutic agents may also be delivered indirectly through a protective or controlling layer in the form of a layer in the openings or a coating on the device.
  • [0110]
    In one embodiment of the invention, one or more angiogenic agents are provided in openings open to the exterior surface 24 of the medical device and one or more vasodilator agents are provided in openings open to the inside surface 26 of the medical device 10. In another embodiment of the invention, one or more antiproliferative, anti-inflammatory, and/or antiangiogenic agents are provided in openings open to the exterior surface 24 of the medical device 10 and one or more vasodilator agents are provided in openings open to the inside surface 26 of the medical device.
  • [0111]
    In a further embodiment of the invention, one or more angiogenic agents are provided in openings open to the exterior surface 24 of the medical device 10 and one or more antithrombotic and/or antiplatelet agents are provided in openings open to the inside surface 26 of the medical device. In another embodiment of the invention, one or more antiproliferative, anti-inflammatory, and/or antiangiogenic agents are provided in openings open to the exterior surface 24 of the medical device 10 and one or more antithrombotic and/or antiplatelet agents are provided in openings open to the inside surface 26 of the medical device.
  • [0112]
    In yet another embodiment of the invention, one or more antirestenotic agents, including but not limited to actinomycin D, Rapamycin or paclitaxel, are provided in openings open to the exterior surface 24 of the medical device 10 and one or more vasodilators are provided in openings open to the inside surface 26 of the medical device. In another embodiment of the invention, one or more antirestenotic agents are provided in openings open to the exterior surface 24 of the medical device 10 and one or more antithrombotic and/or antiplatelet agents are provided in openings open to the inside surface 26 of the medical device.
  • [0113]
    As used herein, one or more agents include agents comprising different agents, different combinations of agents, different concentrations of the same or different agents, or combinations thereof, in one or more therapeutic layers.
  • [0114]
    In one embodiment of the invention, multiple therapeutic layers are used to provide the essentially sequential release of one or more therapeutic agents. In this manner, multiple antirestenotic, angiogenic or antiangiogenic, anti-inflammatory, and/or antiproliferative agents are delivered sequentially to the blood vessel wall while multiple, antithrombotic agents, anti-inflammatories, antiplatelet agents, and/or vasodilators are sequentially delivered to the lumen of the blood vessel. The sequence and release profiles of each therapeutic agent may be modulated by providing each therapeutic agent in specific openings, in layers with different bioerodable characteristics, in layers deposited in a specific order with respect to adjacent layers, or through any combination thereof. Accordingly, the instant invention allows the practitioner to tailor the release of therapeutic agents to particular types of treatment, to particular combinations of treatments, to the needs of particular patients, and any combinations thereof.
  • [0115]
    The presence of openings also allows layers of bioresorbable matrix to be deposited beyond the outer edge of the medical device as the matrix material disposed within the openings serves as an anchor for a cone or other protruding shape of matrix material outside the openings. The cone of matrix material could comprise, for example, the first of a number of therapeutic agents (or the first combination of therapeutic agents) to be delivered to a target capillary. Upon implantation of the medical device, the cones are forced into contact with the interior surface of the capillary, delivering the therapeutic agent in a concentrated form with minimal opportunity for diffusion of the therapeutic agents away from the target cells. In addition, cones of sufficient stiffness, as determined by the matrix material, are able to mechanically penetrate the intema or the intema and media of the target blood vessel and deliver a therapeutic agent directly to the adventitia, where therapeutic agents may be most likely to have an effect. As the outer cone of material dissolves, new layers of biodegradable matrix are exposed, delivering additional therapeutic agents to the vessel wall. In one embodiment of the invention, only the outermost layer is conical in shape. In another embodiment, more than one layer is conical in shape.
  • [0116]
    In one embodiment, the openings or wells contain one or more therapeutic polypeptides, including but not limited to angiogenic polypeptides. As used herein, polypeptides include full-length polypeptides, truncated polypeptides, chimeric polypeptides, variant polypeptides, polypeptide fragments, conjugated polypeptides, or synthetic polypeptides comprising naturally-occurring or synthetic amino acids. Any of the polypeptides may be glycosylated, phosphorylated, acylated, or otherwise modified. The invention includes the use of individual polypeptides, multiple polypeptides, polypeptides comprising multiple subunits, polypeptides requiring co-factors, and combinations thereof.
  • [0117]
    The polypeptides may be native or recombinant. The polypeptides may be obtained from natural sources or expressed in bacteria, yeast, or animal cells, including but not limited to mammalian cells. In a preferred embodiment of the invention, the polypeptides are human polypeptides. In another embodiment of the invention, the polypeptides are non-human primate polypeptides. In yet another embodiment of the invention, the polypeptides are mammalian polypeptides. In another embodiment of the invention, the polypeptides are truncated, chimeric, or variant polypeptides comprising one or more of the polypeptides referred to above.
  • [0118]
    The polypeptides may be active or inactive. Inactive polypeptides are useful, for example, for clinical experiments that require control medical devices having one or more inactive therapeutic agents. The polypeptides may further include a proteolytic cleavage site, destruction sequence, or secondary binding site for one or more modulating agents to allow modulation of polypeptide activity, specificity, or stability, coincident with or following medical device implantation.
  • [0119]
    The agents may be conjugated to other molecules to, for example, modulate their stability, hydrophilicity, hydrophobicity, activity, or ability to interact with particular receptors, cells types, or tissues. For example, polypeptides may be conjugated to heparin or heparin sulfate. In another embodiment, polypeptides are conjugated to naturally occurring or synthetic polymers. In another embodiment of the invention, polypeptides are conjugated to lipids or synthetic water soluble polymers, such as PEG or PET. The practitioner will recognize that any polypeptide conjugate known in the art to be useful for, e.g., polypeptide stability, delivery, or modulation, may be used within the scope of the invention. Any number of different conjugates may be used in the instant invention. In addition, any subset or all the polypeptides used as part of the instant invention may be fully conjugated, partially conjugated, or conjugated with different molecules and disposed in the same layer or in different layers.
  • [0120]
    Polypeptide therapeutic agents that can be used as part of the invention can be provided using polynucleotides encoding the polypeptides. Polynucleotides may be delivered using a gene therapy delivery vector, including but not limited to a retrovirus vector or an adenovirus vector. Polypeptide therapeutic agents can be combined with therapeutic polynucleotides and/or therapeutic small molecules that function through similar mechanism or different mechanisms.
  • [0121]
    According to one embodiment of the invention, angiogenic agents are delivered to a site of implantation. In a preferred embodiment of the invention, angiogenic agents are delivered to the exterior surface of the medical device. The delivery of angiogenic agents is useful, for example, for promoting the growth of blood vessels to alleviate disorders and conditions associated with chronic total occlusions, including but are not limited to distal embolization, arterial ruptures, acute myocardial infarction, myocardial infarction, groin hematomas, contrast-induced nephropathies, angina pectoris, digital microcirculation, chronic thromboembolic pulmonary hypertension, chronic subcritical ischemia, death, and other disorders of conditions resulting from chronic total coronary occlusion of coronary arteries.
  • [0122]
    The angiogenic agents may comprise one or more angiogenic polypeptides. The angiogenic polypeptides may be native or recombinant polypeptides. Examples of angiogenic polypeptides include VEGF, FGF, and HGF, matrix metalloproteinases (e.g., tPA, uPA), Ang, 1, Ang2, tissue factor, TGF-β1, PDGF-B, hepatocyte growth factor (HGF), insulin-like growth factor, epidermal growth factor, PD-ECGF, PF4, TSP-1, TNF, proliferin, plasminogen activator, IL-8, and HGF. In a preferred embodiment, the openings or wells contain VEGF polypeptides in a biodegradable matrix.
  • [0123]
    Angiogenic polypeptides may be provided using polynucleotides encoding angiogenic polypeptides. Polynucleotides may be delivered using a gene delivery vector, including but not limited to a retrovirus vector or an adenovirus vector. The angiogenic agents may also comprise angiogenic small molecules. Angiogenic agents may comprise combinations of angiogenic polypeptides, polynucleotides, and small molecules. Angiogenic agents may be delivered over a period of weeks or months following medical device implantation to stimulate local angiogenesis.
  • [0124]
    In another embodiment of the invention, vasodilators are delivered to the site of implantation. Vasodilators for use in the instant invention include but are not limited to organic nitrates (e.g., nitroglycerin, isosorbide dinitrate, isosorbide dinitrate), prostaglandins (e.g., epoprostenol, prostaglandin 12 (prostacyclin), and prostaglandin E2), phosphodiesterase inhibitors (e.g., pamrinone, mirinone, enoximone and piroximone), calcium antagonists (e.g., dihydropyridine, nifedipine amlodipine, felodipine, isradipine, nilvadipine, nisoldipine and nitrendipine), dopamine receptor agonists (e.g., fenoldopam mesylate), angiotensin-converting enzme (ACE) inhibitors (temocaprilat, enalaprilat, captopril quinapril, and perindopril), angiotensin-II receptor antagonists (losartan, RNH-6270, L158,809, PD123319), -adrenergic receptor antagonists (e.g., bunazosin), 1-adrenergic agonist e.g., carvedilol, metoprolol, and bisoprolol), and bradykinin. Kitakaze, M. et al. (2002) J. Am. Coll. Cardiol. 40:162-6; Oikawa, Y. et al. (2001) J. Am. Coll. Cardiol. 38:1188-94; Tanoue, A. et al. (2001) J. Clin. Invest. 109:765-75; Sun, Y. P. et al. (2001) J. Cardiovasc. Pharmacol. Ther. 6:175-81; Kirsten, R. et al. (1998) Pharmacokinet. 34:457-82; Kirsten, R. (1998) Pharmacokinet. 35:9-36; Physicians' Desk Reference (2001) Medical Economics Co., Inc., Montvale, N.J.; and references within.
  • [0125]
    Additional vasodilators known in the art include but are not limited to contulakin-G (U.S. Pat. No. 6,489,298), L-arginine and type V phosphodiesterases (U.S. Pat. No. 6,476,037), include thiophene compounds (U.S. Pat. No. 6,440,948), 4,5-diaryl oxazole derivatives (U.S. Pat. No. 5,972,965), N6-substituted adenosine analogues (U.S. Pat. No. 5,284,834), and nitrosothiol derivatives (U.S. Pat. No. 5,116,861), 1,4-Dihydropyridine compounds (U.S. Pat. No. 4,446,325). Any clinically acceptable vasodilator can be used to practice the instant invention, provided the vasodilator can be provided using the medical devices of the instant invention.
  • [0126]
    In another embodiment of the invention, anticoagulant agents (or anticoagulants) can be delivered to a site of implantation. Anticoagulants include compounds that inhibit vitamin K-dependent coagulation factors (e.g., coumarins), indirect inhibitors of thrombin (e.g., heparins and heparin derivatives), and direct thrombin inhibitors (DTIs) (e.g., hirudin, DuP 714, PPACK, efegatran, inogatran, melagatran, and ximelagatran). Physicians' Desk Reference (2001) Medical Economics Co., Inc., Montvale, N.J.; Van Aken, H. et al. (2001) Clin. Appl. Thromb. Hemost. 7:195-204; and references within. Any clinically acceptable anticoagulants can be used to practice the instant invention, provided the anticoagulants can be provided using the medical devices of the instant invention.
  • [0127]
    In yet another embodiment of the invention, antiplatelet agents can be delivered to a site of implantation. Antiplatelet agents include ADP receptor antagonists (e.g., ticlopidine and clopidogrel), glycoprotein (GP) IIb/IIIa receptor agonists (e.g., eptifibatide, tirofiban, and abciximab) that function through a variety of mechanisms, as well as prostaglandin inhibitors (e.g., aspirin) and phosphodiesterase inhibitors (e.g., dipyridamole and cilostazol). Physicians' Desk Reference (2001) Medical Economics Co., Inc., Montvale, N.J.; Dogne, J. M. et al.
  • [0128]
    Curr. Med. Chem. 9:577-89; and references within. Any clinically acceptable antiplatelet agents can be used to practice the instant invention, provided the antiplatelet agents can be provided using the medical devices of the instant invention.
  • [0129]
    In another embodiment of the invention, immunosuppressive agents can be delivered to a site of implantation. Immunosuppressive agents include but are not limited to methotrexate and its polyglutamate derivatives, glucocorticoids, cyclophosphamide and azathioprine metabolites, mycophenolic acid, mizoribine, Brequinar, a leflunomide metabolite, cyclosporine, Tacrolimus, and Rapamycin. Allison, A. C. (2000) Immunopharmacology. 47:63-83; and references within.
  • [0130]
    Any of the above identified therapeutic agents may be conjugated to other molecules to, for example, increase their stability, increase their hydrophilicity, increase their hydrophobicity, modulate their activity, modulate there ability to interact with particular cell types, or to cause the therapeutic agent to be delivered simultaneously with a second therapeutic agent that causes no therapeutic effects or causes therapeutic effects through a different mechanism. For example, angiogenic polypeptides may be conjugated to heparin or heparin sulfate. In this case, heparin stabilizes the angiogenic polypeptide while also functioning as an antiplatelet agent.
  • [0131]
    While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.

Claims (38)

1. A method of delivering therapeutic agents comprising the steps of:
a) providing a medical device comprising an exterior surface and an interior surface, and first and second therapeutic agents in openings in the medical device;
b) implanting the medical device with the therapeutic agents in a patient;
c) releasing the first therapeutic agent predominantly in a direction of said exterior surface of the medical device over a time period sufficient to produce a therapeutic effect; and
d) releasing the second therapeutic agent predominantly in a direction of said interior surface of the medical device over a time period sufficient to produce a therapeutic effect.
2. The method of claim 1, wherein the openings in the medical device are through openings traversing the exterior surface and the interior surface.
3. The method of claim 1, wherein the openings in the medical device are non-traversing recesses in the exterior surface or the interior surface of the medical device.
4. The method of claim 2, wherein the first and second therapeutic agents are selected from the group consisting of:
a) different therapeutic agents;
b) different concentrations of therapeutic agents;
c) different release profiles of therapeutic agents; and
d) combinations of a)-c).
5. The method of claim 1, wherein the openings are provided with a barrier layer disposed at a radially intermediate location with respect to said exterior surface and said interior surface of the medical device, and wherein said first therapeutic agent is provided at a radially exterior surface with respect to the barrier layer and said second therapeutic agent is provided at a radially interior surface with respect to the barrier layer.
6. The method of claim 1, wherein a first subset of the openings are provided with a first barrier layer disposed near the interior surface of the medical device and said first therapeutic agent is provided at a radially exterior position with respect to the first barrier layer and a second subset of openings are provided with a second barrier layer disposed near the exterior surface of the medical device and said second therapeutic agent is provided at a radially interior position with respect to the second barrier layer.
7. A method of delivering two or more therapeutic agents, to a blood vessel comprising the steps of:
a) providing a substantially cylindrical medical device having an exterior surface, an interior surface, and openings traversing said exterior surface and said interior surface, said openings having a barrier layer arranged at a radially intermediate surface with respect to said exterior surface and said interior surface, wherein at least one first therapeutic agent is disposed in a therapeutic layer disposed at a radially exterior surface with respect to said barrier layer and wherein at least one second therapeutic agent is disposed in a therapeutic layer disposed at a radially interior surface with respect to said barrier layer;
b) delivering the medical device with the therapeutic agents to a lumen of a blood vessel; and
c) releasing the therapeutic agents over a time period sufficient to produce a therapeutic effect, wherein the first therapeutic agent is released substantially toward said exterior surface of the medical device and wherein the second therapeutic agent is released substantially toward said interior surface of the medical device.
8. The method of claim 7, wherein the first and second therapeutic agents are selected from the group consisting of:
a) different therapeutic agents;
b) different concentrations of therapeutic agents;
c) different release profiles of therapeutic agents; and
d) combinations of a)-c).
9. The method of claim 7, wherein the first therapeutic agent is selected from the group consisting of:
a) an antiproliferative agent;
b) an antiangiogenic agent;
c) an angiogenic agent;
d) an antirestenotic agent;
e) anti-inflammatory; and
f) combinations of a)-e).
10. The method of claim 9, wherein the second therapeutic agent is selected from the group consisting of:
a) an antithrombotic agent;
b) an antiplatelet agent;
c) a vasodilator;
d) anti-inflammatory; and
e) combinations of a)-d).
11. A method of delivering therapeutic agents to a blood vessel comprising the steps of:
a) providing a medical device comprising a first surface, a second surface, and openings traversing said first surface and said second surface, said openings containing therapeutic agents;
b) delivering the medical device with the therapeutic agents to a lumen of a blood vessel; and
c) releasing a first of the therapeutic agents to a wall of the blood vessel over a time period sufficient to produce a therapeutic effect; and
d) releasing a second of the therapeutic agents to the lumen of the blood vessel over a time period sufficient to produce a therapeutic effect.
12. The method of claim 11, wherein the first and second therapeutic agents are selected from the group consisting of:
a) different therapeutic agents;
b) different concentrations of therapeutic agents;
c) different release profiles of therapeutic agents; and
d) combinations of a)-c).
13. The method of claim 11, wherein the first therapeutic agent is selected from the group consisting of:
a) an antiproliferative agent;
b) an antiangiogenic agent;
c) an angiogenic agent;
d) an antirestenotic agent;
e) anti-inflammatory; and
f) combinations of a)-e).
14. The method of claim 13, wherein the second therapeutic agent is selected from the group consisting of:
a) an antithrombotic agent;
b) an antiplatelet agent;
c) a vasodilator;
d) anti-inflammatory; and
e) combinations of a)-d).
15. The method of claim 11, wherein the openings are provided with a barrier layer disposed at a radially intermediate location with respect to said first surface and said second surface of the medical device, and wherein said first therapeutic agent is provided at a radially exterior surface with respect to the barrier layer and said second therapeutic agent is provided at a radially interior surface with respect to the barrier layer.
16. The method of claim 11, wherein a first subset of the openings are provided with a first barrier layer disposed near the interior surface of the medical device and said first therapeutic agent is provided at a radially exterior position with respect to the first barrier layer and a second subset of openings are provided with a second barrier layer disposed near the exterior surface of the medical device and said second therapeutic agent is provided at a radially interior position with respect to the second barrier layer.
17. A drug delivery device comprising:
a medical device having an exterior surface and an interior surface;
a plurality of openings in the device body; and
a first therapeutic agent and a second therapeutic agent disposed in the openings and arranged to deliver the first therapeutic agent primarily to the exterior surface and to deliver the second therapeutic agent primarily to the interior surface.
18. The device of claim 17, wherein the openings in the medical device are through openings traversing the exterior surface and the interior surface.
19. The device of claim 17, wherein the first and second therapeutic agents selected from the group consisting of:
a) different therapeutic agents;
b) different concentrations of therapeutic agents;
c) different release profiles of therapeutic agents;
d) anti-inflammatory; and
e) combinations of a)-d).
20. The device of claim 17, wherein the first therapeutic agent is selected from the group consisting of an angiogenic agent an anti-inflammatory agent, and an antiproliferative agent.
21. The device of claim 20, wherein the second therapeutic agent is selected from the group consisting of an antirestenotic agent, an antithrombotic agent, an antiplatelet agent, an anti-inflammatory agent, and a vasodilator.
22. The device of claim 17, wherein the openings are provided with a barrier layer disposed at a radially intermediate position with respect to said exterior surface and said interior surface of the medical device, and wherein said first therapeutic agent is provided at a radially exterior position with respect to the barrier layer and said second therapeutic agent is provided at a radially interior position with respect to the barrier layer.
23. The device of claim 17, wherein a first subset of the openings are provided with a first barrier layer disposed near the interior surface of the medical device and said first therapeutic agent is provided at a radially exterior position with respect to the first barrier layer and a second subset of openings are provided with a second barrier layer disposed near the exterior surface of the medical device and said second therapeutic agent is provided at a radially interior position with respect to the second barrier layer.
24. A drug delivery device comprising:
an exterior surface;
an interior surface;
a plurality of openings traversing said exterior surface and said interior surface, said openings having a barrier layer arranged at a radially intermediate position with respect to said exterior surface and said interior surface;
at least one first therapeutic agent in a therapeutic layer disposed at a radially exterior position with respect to said barrier layer; and
and at least one second therapeutic agent in a therapeutic layer disposed at a radially interior position with respect to said barrier layer.
25. The device of claim 24, wherein the first therapeutic agent is selected from the group consisting of an angiogenic agent, an anti-inflammatory agent, and an antiproliferative agent.
26. The device of claim 25, wherein the second therapeutic agent is selected from the group consisting of an antirestenotic agent, an antithrombotic agent, an antiplatelet agent, an anti-inflammatory agent, and a vasodilator.
27. The method of claim 1, wherein the first therapeutic agent is selected from the group consisting of an angiogenic agent and an antiproliferative agent.
28. The method of claim 27, wherein the second agent is selected from the group consisting of an antithrombotic agent, an antiplatelet agent, a vasodilator, and an anti-inflammatory agent.
29. The device of claim 18, wherein the through openings have a substantially uniform cross section between the interior and exterior surfaces.
30. The device of claim 22, wherein the barrier layer is bioerodible.
31. The device of claim 30, wherein the barrier layer has a predetermined erosion time which is longer than erosion times of biodegradable matrices containing the first and second therapeutic agents.
32. The device of claim 17, wherein the first therapeutic agent is contained within a biodegradable matrix and the first therapeutic agent has a concentration variation within the matrix.
33. The device of claim 17, wherein the second therapeutic agent is contained within a biodegradable matrix and the second therapeutic agent has a concentration variation within the matrix.
34. The device of claim 17, wherein the openings are substantially non-deforming openings.
35. The device of claim 24, wherein the openings are substantially non-deforming openings.
36. The device of claim 24, wherein the barrier layer substantially prevents passage of the first and second therapeutic agents there through.
37. The device of claim 24, wherein the barrier layer is bioerodible.
38. The device of claim 37, wherein the barrier has a predetermined erosion time which is longer than erosion times of biodegradable matrices containing the first and second therapeutic agents.
US10456432 2003-06-05 2003-06-05 Drug delivery device and method for bi-directional drug delivery Active 2024-07-27 US7169179B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10456432 US7169179B2 (en) 2003-06-05 2003-06-05 Drug delivery device and method for bi-directional drug delivery

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10456432 US7169179B2 (en) 2003-06-05 2003-06-05 Drug delivery device and method for bi-directional drug delivery
EP20040753827 EP1635893B1 (en) 2003-06-05 2004-06-02 Drug delivery device for bi-directional drug delivery
CA 2528166 CA2528166C (en) 2003-06-05 2004-06-02 Drug delivery device and method for bi-directional drug delivery
PCT/US2004/017085 WO2004108186A3 (en) 2003-06-05 2004-06-02 Drug delivery device and method for bi-directional drug delivery
JP2006515031A JP4699994B2 (en) 2003-06-05 2004-06-02 How the drug feeder and drug two quarters supply
JP2010167134A JP5433520B2 (en) 2003-06-05 2010-07-26 How the drug feeder and drug two quarters supply

Publications (2)

Publication Number Publication Date
US20040249449A1 true true US20040249449A1 (en) 2004-12-09
US7169179B2 US7169179B2 (en) 2007-01-30

Family

ID=33490173

Family Applications (1)

Application Number Title Priority Date Filing Date
US10456432 Active 2024-07-27 US7169179B2 (en) 2003-06-05 2003-06-05 Drug delivery device and method for bi-directional drug delivery

Country Status (5)

Country Link
US (1) US7169179B2 (en)
JP (2) JP4699994B2 (en)
CA (1) CA2528166C (en)
EP (1) EP1635893B1 (en)
WO (1) WO2004108186A3 (en)

Cited By (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040093071A1 (en) * 2000-06-05 2004-05-13 Jang G. David Intravascular stent with increasing coating retaining capacity
US20040225347A1 (en) * 2000-06-05 2004-11-11 Lang G. David Intravascular stent with increasing coating retaining capacity
US20050059991A1 (en) * 1999-05-20 2005-03-17 Shanley John F. Expandable medical device delivery system and method
US20050278929A1 (en) * 2004-06-16 2005-12-22 National Taipei University Technology Process of manufacturing stent with therapeutic function in the human body
US20060079956A1 (en) * 2004-09-15 2006-04-13 Conor Medsystems, Inc. Bifurcation stent with crushable end and method for delivery of a stent to a bifurcation
US20060210600A1 (en) * 2003-07-07 2006-09-21 Medtronic Vascular, Inc. Coated stent with timed release of multiple therapeutic agents to inhibit restenosis adjacent to the stent ends
WO2007033152A2 (en) * 2005-09-12 2007-03-22 Conor Medsystems, Inc. Composition, system and method for modulating release kinetics in implantable drug delivery devices by modifying drug solubility
US20070122449A1 (en) * 2005-11-28 2007-05-31 Choonara Yahya E Biodegradable implantable drug delivery device
US20080269875A1 (en) * 2007-04-30 2008-10-30 Zhao Jonathon Z Coating for a Medical Device Having an Anti-Thrombotic Conjugate
US20090018646A1 (en) * 2007-07-10 2009-01-15 Zhao Jonathon Z Coating Employing an Anti-Thrombotic Conjugate
US7658758B2 (en) 2001-09-07 2010-02-09 Innovational Holdings, Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US20100082096A1 (en) * 2008-09-30 2010-04-01 Boston Scientific Scimed, Inc. Tailored Luminal & Abluminal Drug Elution
US7753285B2 (en) 2007-07-13 2010-07-13 Bacoustics, Llc Echoing ultrasound atomization and/or mixing system
US7758636B2 (en) 2002-09-20 2010-07-20 Innovational Holdings Llc Expandable medical device with openings for delivery of multiple beneficial agents
US7780095B2 (en) 2007-07-13 2010-08-24 Bacoustics, Llc Ultrasound pumping apparatus
US20100217380A1 (en) * 2009-02-02 2010-08-26 Ryan Donovan Flexible stent design
US7815675B2 (en) 1996-11-04 2010-10-19 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
US20100280600A1 (en) * 2009-04-30 2010-11-04 Vipul Bhupendra Dave Dual drug stent
US7833266B2 (en) 2007-11-28 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
US7842082B2 (en) 2006-11-16 2010-11-30 Boston Scientific Scimed, Inc. Bifurcated stent
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7896539B2 (en) 2005-08-16 2011-03-01 Bacoustics, Llc Ultrasound apparatus and methods for mixing liquids and coating stents
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7951193B2 (en) 2008-07-23 2011-05-31 Boston Scientific Scimed, Inc. Drug-eluting stent
US7951191B2 (en) 2006-10-10 2011-05-31 Boston Scientific Scimed, Inc. Bifurcated stent with entire circumferential petal
US7951192B2 (en) 2001-09-24 2011-05-31 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
US7959669B2 (en) 2007-09-12 2011-06-14 Boston Scientific Scimed, Inc. Bifurcated stent with open ended side branch support
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8016878B2 (en) 2005-12-22 2011-09-13 Boston Scientific Scimed, Inc. Bifurcation stent pattern
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US8057534B2 (en) 2006-09-15 2011-11-15 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US20120029622A1 (en) * 2010-08-02 2012-02-02 Baillargeon Brian P Flexible helical stent having different helical regions
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8187321B2 (en) 2000-10-16 2012-05-29 Innovational Holdings, Llc Expandable medical device for delivery of beneficial agent
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US20120172794A1 (en) * 2008-02-21 2012-07-05 Hexacath Implantable medical device including a protection/retaining layer for an active ingredient or drug, in particular a water-soluble one
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8277501B2 (en) 2007-12-21 2012-10-02 Boston Scientific Scimed, Inc. Bi-stable bifurcated stent petal geometry
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8449901B2 (en) 2003-03-28 2013-05-28 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
KR20130096717A (en) * 2010-08-02 2013-08-30 코디스 코포레이션 Flexible helical stent having intermediate structural feature
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
KR20130138188A (en) * 2010-08-02 2013-12-18 코디스 코포레이션 Flexible helical stent having intermediate structural feature
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US8932340B2 (en) 2008-05-29 2015-01-13 Boston Scientific Scimed, Inc. Bifurcated stent and delivery system
US9101949B2 (en) 2005-08-04 2015-08-11 Eilaz Babaev Ultrasonic atomization and/or seperation system
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132058A1 (en) 2000-03-06 2001-09-12 Advanced Laser Applications Holding S.A. Intravascular prothesis
JP4330970B2 (en) * 2003-10-14 2009-09-16 テルモ株式会社 Stent and a method of manufacturing the same
US20070055352A1 (en) * 2005-09-07 2007-03-08 Wendy Naimark Stent with pockets for containing a therapeutic agent
US20070088442A1 (en) * 2005-10-14 2007-04-19 Microchips, Inc. Passive wear-indicating sensor for implantable prosthetic device
US8221496B2 (en) * 2007-02-01 2012-07-17 Cordis Corporation Antithrombotic and anti-restenotic drug eluting stent
US20100292777A1 (en) * 2009-05-13 2010-11-18 Boston Scientific Scimed, Inc. Stent
US20110137407A1 (en) * 2009-07-09 2011-06-09 Thai Minh Nguyen Bare metal stent with drug eluting reservoirs

Citations (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) * 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4580568A (en) * 1984-10-01 1986-04-08 Cook, Incorporated Percutaneous endovascular stent and method for insertion thereof
US4650466A (en) * 1985-11-01 1987-03-17 Angiobrade Partners Angioplasty device
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US4990155A (en) * 1989-05-19 1991-02-05 Wilkoff Howard M Surgical stent method and apparatus
US4989601A (en) * 1988-05-02 1991-02-05 Medical Engineering & Development Institute, Inc. Method, apparatus, and substance for treating tissue having neoplastic cells
US4994071A (en) * 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5019090A (en) * 1988-09-01 1991-05-28 Corvita Corporation Radially expandable endoprosthesis and the like
US5078726A (en) * 1989-02-01 1992-01-07 Kreamer Jeffry W Graft stent and method of repairing blood vessels
US5092841A (en) * 1990-05-17 1992-03-03 Wayne State University Method for treating an arterial wall injured during angioplasty
US5102417A (en) * 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US5176617A (en) * 1989-12-11 1993-01-05 Medical Innovative Technologies R & D Limited Partnership Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct
US5195984A (en) * 1988-10-04 1993-03-23 Expandable Grafts Partnership Expandable intraluminal graft
US5197978A (en) * 1991-04-26 1993-03-30 Advanced Coronary Technology, Inc. Removable heat-recoverable tissue supporting device
US5213580A (en) * 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5286254A (en) * 1990-06-15 1994-02-15 Cortrak Medical, Inc. Drug delivery apparatus and method
US5292512A (en) * 1988-12-20 1994-03-08 Centre Internationale De Recherches Dermatologiques (C.I.R.D.) Cosmetic or pharmaceutical composition containing microspheres of polymers or of fatty substances filled with at least one active product
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5314688A (en) * 1991-11-21 1994-05-24 Eli Lilly And Company Local delivery of dipyridamole for the treatment of proliferative diseases
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
US5383892A (en) * 1991-11-08 1995-01-24 Meadox France Stent for transluminal implantation
US5403858A (en) * 1991-07-08 1995-04-04 Rhone-Poulenc Rorer, S.A. New compositions containing taxane derivatives
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5523092A (en) * 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5593434A (en) * 1992-01-31 1997-01-14 Advanced Cardiovascular Systems, Inc. Stent capable of attachment within a body lumen
US5607442A (en) * 1995-11-13 1997-03-04 Isostent, Inc. Stent with improved radiopacity and appearance characteristics
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5616608A (en) * 1993-07-29 1997-04-01 The United States Of America As Represented By The Department Of Health And Human Services Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
US5618299A (en) * 1993-04-23 1997-04-08 Advanced Cardiovascular Systems, Inc. Ratcheting stent
US5617878A (en) * 1996-05-31 1997-04-08 Taheri; Syde A. Stent and method for treatment of aortic occlusive disease
US5624411A (en) * 1993-04-26 1997-04-29 Medtronic, Inc. Intravascular stent and method
US5628787A (en) * 1993-01-19 1997-05-13 Schneider (Usa) Inc. Clad composite stent
US5707385A (en) * 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US5713949A (en) * 1996-08-06 1998-02-03 Jayaraman; Swaminathan Microporous covered stents and method of coating
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5725549A (en) * 1994-03-11 1998-03-10 Advanced Cardiovascular Systems, Inc. Coiled stent with locking ends
US5733925A (en) * 1993-01-28 1998-03-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5733330A (en) * 1997-01-13 1998-03-31 Advanced Cardiovascular Systems, Inc. Balloon-expandable, crush-resistant locking stent
US5743293A (en) * 1994-06-24 1998-04-28 Robertshaw Controls Company Fuel control device and methods of making the same
US5759192A (en) * 1994-11-28 1998-06-02 Advanced Cardiovascular Systems, Inc. Method and apparatus for direct laser cutting of metal stents
US5769883A (en) * 1991-10-04 1998-06-23 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5855600A (en) * 1997-08-01 1999-01-05 Inflow Dynamics Inc. Flexible implantable stent with composite design
US5868781A (en) * 1996-10-22 1999-02-09 Scimed Life Systems, Inc. Locking stent
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5876419A (en) * 1976-10-02 1999-03-02 Navius Corporation Stent and method for making a stent
US5882335A (en) * 1994-09-12 1999-03-16 Cordis Corporation Retrievable drug delivery stent
US6017363A (en) * 1997-09-22 2000-01-25 Cordis Corporation Bifurcated axially flexible stent
US6019789A (en) * 1998-04-01 2000-02-01 Quanam Medical Corporation Expandable unit cell and intraluminal stent
US6030414A (en) * 1997-11-13 2000-02-29 Taheri; Syde A. Variable stent and method for treatment of arterial disease
US6042606A (en) * 1997-09-29 2000-03-28 Cook Incorporated Radially expandable non-axially contracting surgical stent
US6056722A (en) * 1997-09-18 2000-05-02 Iowa-India Investments Company Limited Of Douglas Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and methods of use
US6063101A (en) * 1998-11-20 2000-05-16 Precision Vascular Systems, Inc. Stent apparatus and method
US6071305A (en) * 1996-11-25 2000-06-06 Alza Corporation Directional drug delivery stent and method of use
US6174326B1 (en) * 1996-09-25 2001-01-16 Terumo Kabushiki Kaisha Radiopaque, antithrombogenic stent and method for its production
US6193746B1 (en) * 1992-07-08 2001-02-27 Ernst Peter Strecker Endoprosthesis that can be percutaneously implanted in the patient's body
US6206916B1 (en) * 1998-04-15 2001-03-27 Joseph G. Furst Coated intraluminal graft
US6206915B1 (en) * 1998-09-29 2001-03-27 Medtronic Ave, Inc. Drug storing and metering stent
US6206914B1 (en) * 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6231600B1 (en) * 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US6241762B1 (en) * 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6240616B1 (en) * 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US6245101B1 (en) * 1999-05-03 2001-06-12 William J. Drasler Intravascular hinge stent
US6249952B1 (en) * 1997-08-04 2001-06-26 Scimed Life Systems, Inc. Method for manufacturing an expandable stent
US20020007209A1 (en) * 2000-03-06 2002-01-17 Scheerder Ivan De Intraluminar perforated radially expandable drug delivery prosthesis and a method for the production thereof
US20020005206A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Antiproliferative drug and delivery device
US20020022876A1 (en) * 2000-03-01 2002-02-21 Jacob Richter Longitudinally flexible stent
US20020028243A1 (en) * 1998-09-25 2002-03-07 Masters David B. Protein matrix materials, devices and methods of making and using thereof
US20020032414A1 (en) * 1998-08-20 2002-03-14 Ragheb Anthony O. Coated implantable medical device
US20020038145A1 (en) * 2000-06-05 2002-03-28 Jang G. David Intravascular stent with increasing coating retaining capacity
US6379381B1 (en) * 1999-09-03 2002-04-30 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6395326B1 (en) * 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US20020068969A1 (en) * 2000-10-16 2002-06-06 Shanley John F. Expandable medical device with improved spatial distribution
US20020072511A1 (en) * 1999-12-29 2002-06-13 Gishel New Apparatus and method for delivering compounds to a living organism
US20020082679A1 (en) * 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US6506411B2 (en) * 1993-07-19 2003-01-14 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US6506437B1 (en) * 2000-10-17 2003-01-14 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device having depots formed in a surface thereof
US20030028244A1 (en) * 1995-06-07 2003-02-06 Cook Incorporated Coated implantable medical device
US20030036794A1 (en) * 1995-06-07 2003-02-20 Cook Incorporated Coated implantable medical device
US6537256B2 (en) * 1999-11-17 2003-03-25 Microchips, Inc. Microfabricated devices for the delivery of molecules into a carrier fluid
US20030060877A1 (en) * 2001-09-25 2003-03-27 Robert Falotico Coated medical devices for the treatment of vascular disease
US20030068355A1 (en) * 2001-08-20 2003-04-10 Shanley John F. Therapeutic agent delivery device with protective separating layer
US6551838B2 (en) * 2000-03-02 2003-04-22 Microchips, Inc. Microfabricated devices for the storage and selective exposure of chemicals and devices
US6558733B1 (en) * 2000-10-26 2003-05-06 Advanced Cardiovascular Systems, Inc. Method for etching a micropatterned microdepot prosthesis
US6730116B1 (en) * 1999-04-16 2004-05-04 Medtronic, Inc. Medical device for intraluminal endovascular stenting

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441745A (en) 1982-03-30 1995-08-15 Vestar, Inc. Method of delivering micellular particles encapsulating chemotherapeutic agents to tumors in a body
US4542025A (en) 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4834755A (en) 1983-04-04 1989-05-30 Pfizer Hospital Products Group, Inc. Triaxially-braided fabric prosthesis
US4955878A (en) 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
JPH0763489B2 (en) 1986-10-31 1995-07-12 宇部興産株式会社 Medical healing - Breakfast
US5059211A (en) 1987-06-25 1991-10-22 Duke University Absorbable vascular stent
US4969458A (en) 1987-07-06 1990-11-13 Medtronic, Inc. Intracoronary stent and method of simultaneous angioplasty and stent implant
US5460817A (en) 1988-01-19 1995-10-24 Allied Colloids Ltd. Particulate composition comprising a core of matrix polymer with active ingredient distributed therein
US5157049A (en) 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
EP0430968B1 (en) 1988-05-02 1996-11-20 PHANOS TECHNOLOGIES, Inc. Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles
US5053048A (en) 1988-09-22 1991-10-01 Cordis Corporation Thromboresistant coating
CA2008312C (en) 1989-01-26 2000-05-30 Ulrich Sigwart Intravascular endoprothesis
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5171262A (en) 1989-06-15 1992-12-15 Cordis Corporation Non-woven endoprosthesis
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5059166A (en) 1989-12-11 1991-10-22 Medical Innovative Technologies R & D Limited Partnership Intra-arterial stent with the capability to inhibit intimal hyperplasia
US5049132A (en) 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
DE69108423T2 (en) 1990-02-08 1995-07-27 Howmedica Inflatable dilator.
US5344426A (en) 1990-04-25 1994-09-06 Advanced Cardiovascular Systems, Inc. Method and system for stent delivery
US5242399A (en) 1990-04-25 1993-09-07 Advanced Cardiovascular Systems, Inc. Method and system for stent delivery
WO1991017724A1 (en) 1990-05-17 1991-11-28 Harbor Medical Devices, Inc. Medical device polymer
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5464450A (en) 1991-10-04 1995-11-07 Scimed Lifesystems Inc. Biodegradable drug delivery vascular stent
WO1993006792A1 (en) 1991-10-04 1993-04-15 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5260002A (en) 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
EP0566245B1 (en) 1992-03-19 1999-10-06 Medtronic, Inc. Intraluminal stent
US5282823A (en) 1992-03-19 1994-02-01 Medtronic, Inc. Intravascular radially expandable stent
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
KR940003548U (en) 1992-08-14 1994-02-21 김형술 Laundry dryers
US5342621A (en) 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5578075B1 (en) 1992-11-04 2000-02-08 Daynke Res Inc Minimally invasive bioactivated endoprosthesis for vessel repair
US5342348A (en) 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5457113A (en) 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5443497A (en) 1993-11-22 1995-08-22 The Johns Hopkins University Percutaneous prosthetic by-pass graft and method of use
US5449373A (en) 1994-03-17 1995-09-12 Medinol Ltd. Articulated stent
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
US5545210A (en) 1994-09-22 1996-08-13 Advanced Coronary Technology, Inc. Method of implanting a permanent shape memory alloy stent
US5817152A (en) 1994-10-19 1998-10-06 Birdsall; Matthew Connected stent apparatus
US5575771A (en) 1995-04-24 1996-11-19 Walinsky; Paul Balloon catheter with external guidewire
US5776181A (en) 1995-07-25 1998-07-07 Medstent Inc. Expandable stent
US5643314A (en) 1995-11-13 1997-07-01 Navius Corporation Self-expanding stent
US5741293A (en) 1995-11-28 1998-04-21 Wijay; Bandula Locking stent
US5725548A (en) 1996-04-08 1998-03-10 Iowa India Investments Company Limited Self-locking stent and method for its production
US5697971A (en) 1996-06-11 1997-12-16 Fischell; Robert E. Multi-cell stent with cells having differing characteristics
US5797898A (en) * 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5807404A (en) 1996-09-19 1998-09-15 Medinol Ltd. Stent with variable features to optimize support and method of making such stent
US5824045A (en) 1996-10-21 1998-10-20 Inflow Dynamics Inc. Vascular and endoluminal stents
US6273908B1 (en) 1997-10-24 2001-08-14 Robert Ndondo-Lay Stents
US7208010B2 (en) * 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040024449A1 (en) * 2001-11-19 2004-02-05 Boyle Christhoper T. Device for in vivo delivery of bioactive agents and method of manufacture thereof
DE20200220U1 (en) * 2002-01-08 2002-03-21 Translumina Gmbh stent

Patent Citations (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) * 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US5876419A (en) * 1976-10-02 1999-03-02 Navius Corporation Stent and method for making a stent
US4580568A (en) * 1984-10-01 1986-04-08 Cook, Incorporated Percutaneous endovascular stent and method for insertion thereof
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US4650466A (en) * 1985-11-01 1987-03-17 Angiobrade Partners Angioplasty device
US4739762A (en) * 1985-11-07 1988-04-26 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4739762B1 (en) * 1985-11-07 1998-10-27 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4733665B1 (en) * 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US5102417A (en) * 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4989601A (en) * 1988-05-02 1991-02-05 Medical Engineering & Development Institute, Inc. Method, apparatus, and substance for treating tissue having neoplastic cells
US5213580A (en) * 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5019090A (en) * 1988-09-01 1991-05-28 Corvita Corporation Radially expandable endoprosthesis and the like
US5195984A (en) * 1988-10-04 1993-03-23 Expandable Grafts Partnership Expandable intraluminal graft
US5292512A (en) * 1988-12-20 1994-03-08 Centre Internationale De Recherches Dermatologiques (C.I.R.D.) Cosmetic or pharmaceutical composition containing microspheres of polymers or of fatty substances filled with at least one active product
US5078726A (en) * 1989-02-01 1992-01-07 Kreamer Jeffry W Graft stent and method of repairing blood vessels
US4990155A (en) * 1989-05-19 1991-02-05 Wilkoff Howard M Surgical stent method and apparatus
US4994071A (en) * 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5176617A (en) * 1989-12-11 1993-01-05 Medical Innovative Technologies R & D Limited Partnership Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct
US5092841A (en) * 1990-05-17 1992-03-03 Wayne State University Method for treating an arterial wall injured during angioplasty
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
US5286254A (en) * 1990-06-15 1994-02-15 Cortrak Medical, Inc. Drug delivery apparatus and method
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5197978B1 (en) * 1991-04-26 1996-05-28 Advanced Coronary Tech Removable heat-recoverable tissue supporting device
US5197978A (en) * 1991-04-26 1993-03-30 Advanced Coronary Technology, Inc. Removable heat-recoverable tissue supporting device
US5403858A (en) * 1991-07-08 1995-04-04 Rhone-Poulenc Rorer, S.A. New compositions containing taxane derivatives
US5769883A (en) * 1991-10-04 1998-06-23 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5383892A (en) * 1991-11-08 1995-01-24 Meadox France Stent for transluminal implantation
US5314688A (en) * 1991-11-21 1994-05-24 Eli Lilly And Company Local delivery of dipyridamole for the treatment of proliferative diseases
US5593434A (en) * 1992-01-31 1997-01-14 Advanced Cardiovascular Systems, Inc. Stent capable of attachment within a body lumen
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
US6193746B1 (en) * 1992-07-08 2001-02-27 Ernst Peter Strecker Endoprosthesis that can be percutaneously implanted in the patient's body
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5628787A (en) * 1993-01-19 1997-05-13 Schneider (Usa) Inc. Clad composite stent
US5733925A (en) * 1993-01-28 1998-03-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5523092A (en) * 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5618299A (en) * 1993-04-23 1997-04-08 Advanced Cardiovascular Systems, Inc. Ratcheting stent
US5624411A (en) * 1993-04-26 1997-04-29 Medtronic, Inc. Intravascular stent and method
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6544544B2 (en) * 1993-07-19 2003-04-08 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6506411B2 (en) * 1993-07-19 2003-01-14 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US5616608A (en) * 1993-07-29 1997-04-01 The United States Of America As Represented By The Department Of Health And Human Services Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5725549A (en) * 1994-03-11 1998-03-10 Advanced Cardiovascular Systems, Inc. Coiled stent with locking ends
US5743293A (en) * 1994-06-24 1998-04-28 Robertshaw Controls Company Fuel control device and methods of making the same
US5882335A (en) * 1994-09-12 1999-03-16 Cordis Corporation Retrievable drug delivery stent
US5707385A (en) * 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US5759192A (en) * 1994-11-28 1998-06-02 Advanced Cardiovascular Systems, Inc. Method and apparatus for direct laser cutting of metal stents
US6231600B1 (en) * 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US20030036794A1 (en) * 1995-06-07 2003-02-20 Cook Incorporated Coated implantable medical device
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US20030028244A1 (en) * 1995-06-07 2003-02-06 Cook Incorporated Coated implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5607442A (en) * 1995-11-13 1997-03-04 Isostent, Inc. Stent with improved radiopacity and appearance characteristics
US5617878A (en) * 1996-05-31 1997-04-08 Taheri; Syde A. Stent and method for treatment of aortic occlusive disease
US5713949A (en) * 1996-08-06 1998-02-03 Jayaraman; Swaminathan Microporous covered stents and method of coating
US6174326B1 (en) * 1996-09-25 2001-01-16 Terumo Kabushiki Kaisha Radiopaque, antithrombogenic stent and method for its production
US5868781A (en) * 1996-10-22 1999-02-09 Scimed Life Systems, Inc. Locking stent
US6022371A (en) * 1996-10-22 2000-02-08 Scimed Life Systems, Inc. Locking stent
US6071305A (en) * 1996-11-25 2000-06-06 Alza Corporation Directional drug delivery stent and method of use
US5766239A (en) * 1997-01-13 1998-06-16 Advanced Cardiovascular Systems, Inc. Balloon-expandable, crush resistant locking stent and method of loading the same
US5733330A (en) * 1997-01-13 1998-03-31 Advanced Cardiovascular Systems, Inc. Balloon-expandable, crush-resistant locking stent
US6240616B1 (en) * 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US5855600A (en) * 1997-08-01 1999-01-05 Inflow Dynamics Inc. Flexible implantable stent with composite design
US6249952B1 (en) * 1997-08-04 2001-06-26 Scimed Life Systems, Inc. Method for manufacturing an expandable stent
US6056722A (en) * 1997-09-18 2000-05-02 Iowa-India Investments Company Limited Of Douglas Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and methods of use
US6017363A (en) * 1997-09-22 2000-01-25 Cordis Corporation Bifurcated axially flexible stent
US6042606A (en) * 1997-09-29 2000-03-28 Cook Incorporated Radially expandable non-axially contracting surgical stent
US6030414A (en) * 1997-11-13 2000-02-29 Taheri; Syde A. Variable stent and method for treatment of arterial disease
US6241762B1 (en) * 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6562065B1 (en) * 1998-03-30 2003-05-13 Conor Medsystems, Inc. Expandable medical device with beneficial agent delivery mechanism
US6019789A (en) * 1998-04-01 2000-02-01 Quanam Medical Corporation Expandable unit cell and intraluminal stent
US6206916B1 (en) * 1998-04-15 2001-03-27 Joseph G. Furst Coated intraluminal graft
US20010000802A1 (en) * 1998-04-30 2001-05-03 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6206914B1 (en) * 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6730064B2 (en) * 1998-08-20 2004-05-04 Cook Incorporated Coated implantable medical device
US20020032414A1 (en) * 1998-08-20 2002-03-14 Ragheb Anthony O. Coated implantable medical device
US20020028243A1 (en) * 1998-09-25 2002-03-07 Masters David B. Protein matrix materials, devices and methods of making and using thereof
US6206915B1 (en) * 1998-09-29 2001-03-27 Medtronic Ave, Inc. Drug storing and metering stent
US6063101A (en) * 1998-11-20 2000-05-16 Precision Vascular Systems, Inc. Stent apparatus and method
US6730116B1 (en) * 1999-04-16 2004-05-04 Medtronic, Inc. Medical device for intraluminal endovascular stenting
US20020002400A1 (en) * 1999-05-03 2002-01-03 Drasler William J. Intravascular hinge stent
US6245101B1 (en) * 1999-05-03 2001-06-12 William J. Drasler Intravascular hinge stent
US6379381B1 (en) * 1999-09-03 2002-04-30 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6537256B2 (en) * 1999-11-17 2003-03-25 Microchips, Inc. Microfabricated devices for the delivery of molecules into a carrier fluid
US20030100865A1 (en) * 1999-11-17 2003-05-29 Santini John T. Implantable drug delivery stents
US20020072511A1 (en) * 1999-12-29 2002-06-13 Gishel New Apparatus and method for delivering compounds to a living organism
US20020022876A1 (en) * 2000-03-01 2002-02-21 Jacob Richter Longitudinally flexible stent
US6551838B2 (en) * 2000-03-02 2003-04-22 Microchips, Inc. Microfabricated devices for the storage and selective exposure of chemicals and devices
US20020007209A1 (en) * 2000-03-06 2002-01-17 Scheerder Ivan De Intraluminar perforated radially expandable drug delivery prosthesis and a method for the production thereof
US20020005206A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Antiproliferative drug and delivery device
US6395326B1 (en) * 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US20020038145A1 (en) * 2000-06-05 2002-03-28 Jang G. David Intravascular stent with increasing coating retaining capacity
US20020068969A1 (en) * 2000-10-16 2002-06-06 Shanley John F. Expandable medical device with improved spatial distribution
US6506437B1 (en) * 2000-10-17 2003-01-14 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device having depots formed in a surface thereof
US6558733B1 (en) * 2000-10-26 2003-05-06 Advanced Cardiovascular Systems, Inc. Method for etching a micropatterned microdepot prosthesis
US20020082679A1 (en) * 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US20030068355A1 (en) * 2001-08-20 2003-04-10 Shanley John F. Therapeutic agent delivery device with protective separating layer
US20030060877A1 (en) * 2001-09-25 2003-03-27 Robert Falotico Coated medical devices for the treatment of vascular disease

Cited By (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7815675B2 (en) 1996-11-04 2010-10-19 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US7479127B2 (en) 1999-05-20 2009-01-20 Innovational Holding, Llc Expandable medical device delivery system and method
US20050059991A1 (en) * 1999-05-20 2005-03-17 Shanley John F. Expandable medical device delivery system and method
US7344514B2 (en) 1999-05-20 2008-03-18 Innovational Holdings, Llc Expandable medical device delivery system and method
US20040225347A1 (en) * 2000-06-05 2004-11-11 Lang G. David Intravascular stent with increasing coating retaining capacity
US20040093071A1 (en) * 2000-06-05 2004-05-13 Jang G. David Intravascular stent with increasing coating retaining capacity
US20090254173A1 (en) * 2000-06-05 2009-10-08 Boston Scientific Scimed, Inc. Extendible stent apparatus
US8187321B2 (en) 2000-10-16 2012-05-29 Innovational Holdings, Llc Expandable medical device for delivery of beneficial agent
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7658758B2 (en) 2001-09-07 2010-02-09 Innovational Holdings, Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US8425590B2 (en) 2001-09-24 2013-04-23 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
US7951192B2 (en) 2001-09-24 2011-05-31 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
US7758636B2 (en) 2002-09-20 2010-07-20 Innovational Holdings Llc Expandable medical device with openings for delivery of multiple beneficial agents
US8349390B2 (en) 2002-09-20 2013-01-08 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US9254202B2 (en) 2002-09-20 2016-02-09 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US8449901B2 (en) 2003-03-28 2013-05-28 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
US20060210600A1 (en) * 2003-07-07 2006-09-21 Medtronic Vascular, Inc. Coated stent with timed release of multiple therapeutic agents to inhibit restenosis adjacent to the stent ends
US20050278929A1 (en) * 2004-06-16 2005-12-22 National Taipei University Technology Process of manufacturing stent with therapeutic function in the human body
US20060079956A1 (en) * 2004-09-15 2006-04-13 Conor Medsystems, Inc. Bifurcation stent with crushable end and method for delivery of a stent to a bifurcation
US9101949B2 (en) 2005-08-04 2015-08-11 Eilaz Babaev Ultrasonic atomization and/or seperation system
US7896539B2 (en) 2005-08-16 2011-03-01 Bacoustics, Llc Ultrasound apparatus and methods for mixing liquids and coating stents
WO2007033152A3 (en) * 2005-09-12 2007-10-04 Conor Medsystems Inc Composition, system and method for modulating release kinetics in implantable drug delivery devices by modifying drug solubility
US8673336B2 (en) 2005-09-12 2014-03-18 Innovational Holdings Llc Composition, system, and method for modulating release kinetics in implantable drug delivery devices by modifying drug solubility
WO2007033152A2 (en) * 2005-09-12 2007-03-22 Conor Medsystems, Inc. Composition, system and method for modulating release kinetics in implantable drug delivery devices by modifying drug solubility
US20110086082A1 (en) * 2005-09-12 2011-04-14 Innovational Holdings, Llc Composition, system, and method for modulating release kinetics in implantable drug delivery devices by modifying drug solubility
US20110212154A1 (en) * 2005-11-28 2011-09-01 University Of The Witwatersrand Biodegradable Implantable Drug Delivery Device
US20070122449A1 (en) * 2005-11-28 2007-05-31 Choonara Yahya E Biodegradable implantable drug delivery device
US8016878B2 (en) 2005-12-22 2011-09-13 Boston Scientific Scimed, Inc. Bifurcation stent pattern
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US8057534B2 (en) 2006-09-15 2011-11-15 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US7951191B2 (en) 2006-10-10 2011-05-31 Boston Scientific Scimed, Inc. Bifurcated stent with entire circumferential petal
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US7842082B2 (en) 2006-11-16 2010-11-30 Boston Scientific Scimed, Inc. Bifurcated stent
US8715339B2 (en) 2006-12-28 2014-05-06 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US8911492B2 (en) 2007-04-30 2014-12-16 Cordis Corporation Coating for a medical device having an anti-thrombotic conjugate
US20080269875A1 (en) * 2007-04-30 2008-10-30 Zhao Jonathon Z Coating for a Medical Device Having an Anti-Thrombotic Conjugate
EP1987851A3 (en) * 2007-04-30 2008-12-24 Cordis Corporation A medical device coating having an anti-thrombotic conjugate
US8383156B2 (en) 2007-04-30 2013-02-26 Cordis Corporation Coating for a medical device having an anti-thrombotic conjugate
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US20090018646A1 (en) * 2007-07-10 2009-01-15 Zhao Jonathon Z Coating Employing an Anti-Thrombotic Conjugate
EP2014308A3 (en) * 2007-07-10 2010-10-20 Cordis Corporation A coating employing an anti-thrombotic conjugate
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7753285B2 (en) 2007-07-13 2010-07-13 Bacoustics, Llc Echoing ultrasound atomization and/or mixing system
US7780095B2 (en) 2007-07-13 2010-08-24 Bacoustics, Llc Ultrasound pumping apparatus
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US7959669B2 (en) 2007-09-12 2011-06-14 Boston Scientific Scimed, Inc. Bifurcated stent with open ended side branch support
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7833266B2 (en) 2007-11-28 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
US8277501B2 (en) 2007-12-21 2012-10-02 Boston Scientific Scimed, Inc. Bi-stable bifurcated stent petal geometry
US9011519B2 (en) * 2008-02-21 2015-04-21 Edoardo Camenzind Implantable medical device including a protection/retaining layer for an active ingredient or drug, in particular a water-soluble one
US20120172794A1 (en) * 2008-02-21 2012-07-05 Hexacath Implantable medical device including a protection/retaining layer for an active ingredient or drug, in particular a water-soluble one
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8932340B2 (en) 2008-05-29 2015-01-13 Boston Scientific Scimed, Inc. Bifurcated stent and delivery system
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7951193B2 (en) 2008-07-23 2011-05-31 Boston Scientific Scimed, Inc. Drug-eluting stent
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US20100082096A1 (en) * 2008-09-30 2010-04-01 Boston Scientific Scimed, Inc. Tailored Luminal & Abluminal Drug Elution
WO2010039846A1 (en) * 2008-09-30 2010-04-08 Boston Scientific Scimed, Inc. Tailored luminal & abluminal drug elution
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
KR101774474B1 (en) * 2009-02-02 2017-09-05 코디스 코포레이션 Flexible stent design
US20160015539A1 (en) * 2009-02-02 2016-01-21 Cordis Corporation Flexible stent design
KR20110122715A (en) * 2009-02-02 2011-11-10 코디스 코포레이션 Flexible stent design
KR101678372B1 (en) * 2009-02-02 2016-12-06 코디스 코포레이션 The flexible stent design
US9168161B2 (en) * 2009-02-02 2015-10-27 Cordis Corporation Flexible stent design
US20100217380A1 (en) * 2009-02-02 2010-08-26 Ryan Donovan Flexible stent design
KR101810379B1 (en) 2009-02-02 2017-12-20 코디스 코포레이션 Flexible stent design
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US20100280600A1 (en) * 2009-04-30 2010-11-04 Vipul Bhupendra Dave Dual drug stent
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
KR20130138188A (en) * 2010-08-02 2013-12-18 코디스 코포레이션 Flexible helical stent having intermediate structural feature
US20120029622A1 (en) * 2010-08-02 2012-02-02 Baillargeon Brian P Flexible helical stent having different helical regions
KR20130096717A (en) * 2010-08-02 2013-08-30 코디스 코포레이션 Flexible helical stent having intermediate structural feature
KR101644410B1 (en) * 2010-08-02 2016-08-01 코디스 코포레이션 Flexible helical stent having intermediate structural feature
KR101676265B1 (en) * 2010-08-02 2016-11-15 코디스 코포레이션 Flexible helical stent having intermediate structural feature
US8961590B2 (en) * 2010-08-02 2015-02-24 Cordis Corporation Flexible helical stent having different helical regions

Also Published As

Publication number Publication date Type
JP5433520B2 (en) 2014-03-05 grant
EP1635893A2 (en) 2006-03-22 application
EP1635893A4 (en) 2010-07-07 application
CA2528166A1 (en) 2004-12-16 application
EP1635893B1 (en) 2014-05-07 grant
WO2004108186A2 (en) 2004-12-16 application
JP2006526471A (en) 2006-11-24 application
US7169179B2 (en) 2007-01-30 grant
WO2004108186A3 (en) 2006-01-12 application
JP2010274125A (en) 2010-12-09 application
CA2528166C (en) 2012-08-07 grant
JP4699994B2 (en) 2011-06-15 grant

Similar Documents

Publication Publication Date Title
US7090694B1 (en) Portal design for stent for treating bifurcated vessels
US20020068969A1 (en) Expandable medical device with improved spatial distribution
US20070173923A1 (en) Drug reservoir stent
US20040006382A1 (en) Intraluminar perforated radially expandable drug delivery prosthesis
US20060173528A1 (en) Stent with self-deployable portion
US6893431B2 (en) Medical device for delivering patches
US20100023108A1 (en) Multiple Drug Delivery From A Balloon And A Prosthesis
US7105018B1 (en) Drug-eluting stent cover and method of use
US20050182390A1 (en) Implantable drug delivery device including wire filaments
US20050070991A1 (en) Intravascular stent with extendible end rings
US20050228483A1 (en) Vascular bifurcation prosthesis with multiple thin fronds
US20090132031A1 (en) Stent Having Spiral Channel for Drug Delivery
US6979347B1 (en) Implantable drug delivery prosthesis
US20060025849A1 (en) Vascular bifurcation prosthesis with multiple linked thin fronds
US7135038B1 (en) Drug eluting stent
US20020155212A1 (en) Coating for a stent and a method of forming the same
US7156869B1 (en) Drug-eluting stent and delivery system with tapered stent in shoulder region
US20060241742A1 (en) Stent comprising a coating system
US20020082679A1 (en) Delivery or therapeutic capable agents
US7258697B1 (en) Stent with anchors to prevent vulnerable plaque rupture during deployment
US20030216806A1 (en) Stent
US20030033007A1 (en) Methods and devices for delivery of therapeutic capable agents with variable release profile
US7008397B2 (en) Cardiac implant and methods
US20050246009A1 (en) Multiple drug delivery from a balloon and a prosthesis
US20100030183A1 (en) Method of treating vascular disease at a bifurcated vessel using a coated balloon

Legal Events

Date Code Title Description
AS Assignment

Owner name: CONOR MEDSYSTEMS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHANLEY, JOHN F.;PARKER, THEODORE L.;REEL/FRAME:014795/0026;SIGNING DATES FROM 20031004 TO 20031006

AS Assignment

Owner name: INNOVATIONAL HOLDINGS LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOR MEDSYSTEMS, INC.;REEL/FRAME:019955/0487

Effective date: 20070306

Owner name: INNOVATIONAL HOLDINGS LLC,NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOR MEDSYSTEMS, INC.;REEL/FRAME:019955/0487

Effective date: 20070306

AS Assignment

Owner name: INNOVATIONAL HOLDINGS LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOR MEDSYSTEMS, INC.;REEL/FRAME:023538/0021

Effective date: 20070306

Owner name: INNOVATIONAL HOLDINGS LLC,NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOR MEDSYSTEMS, INC.;REEL/FRAME:023538/0021

Effective date: 20070306

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
SULP Surcharge for late payment

Year of fee payment: 7

FPAY Fee payment

Year of fee payment: 8